This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/4/2026
Hello, my name is Angeline and I will be your conference call facilitator this afternoon. At this time, I would like to welcome everyone to Invista Holdings Corporation's 3rd Quarter 2026 Earnings Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, please press the star and then number 1 on your telephone keypad. If you would like to review your question, please press the star and the number 2. I will now turn the call over to Mr. Jim Gustafson, Vice President of Investor Relations at Invista Holdings. Mr. Gustafson, you may begin your conference call.
Good afternoon. Thank you for joining Invista's third quarter 2026 earnings call. We appreciate your interest in our company. With me today are Paul Keel, our President and Chief Executive Officer, and Eric Hammes, are key financial officer. Our earnings release, the slide presentation supplementing today's call, and reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are available in the investor section of our website, www.indistico.com. The audio portion of this call will be archived in the investor section of our website later today under the heading Events and Presentations. During the presentation, we will describe some of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted our results. Unless otherwise noted, references in these remarks to company-specific financial metrics relate to the third quarter of 2026, and references to period-to-period increases and decreases in financial metrics are year-over-year. During the call, we may describe certain products and solutions that have applications submitted and pending certain regulatory approvals or are available only in certain markets. We will also make forward-looking statements within the meaning of the federal securities laws, including statements regarding events and developments that we believe or anticipate may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results may differ materially from any forward-looking statements These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements except as required by law. With that, I'll turn the call over to Paul.
Thanks, Jim, and hello to everyone joining us today. I'll start with an overview of the quarter, including strategic and operational progress made in support of our longer-term value creation plans. Eric will then take us through the numbers in more detail. I will wrap things up with a few closing thoughts before we take your questions. As shown on slide four, we delivered core sales growth of 2.7% in Q3, with adjusted EBITDA growth of 9% and adjusted EPS growth of 25%. On a global scale, we did not observe any material shifts in the dental market in Q3 relative to the first half of the year. From a sector perspective, insurance-covered categories like prevention, diagnostics, and restoration display their characteristic resilience, while more elective categories like ortho and implants continue to run below their higher historical trends. From a geographic perspective, developing markets, excluding China, continue to grow most quickly, followed by Europe. As indicated in the latest ADA survey, on a relative basis, the U.S. market remains soft, as macro uncertainty is impacting both patient and clinician confidence. China was also slow in Q3, as it is now in the middle of two dental VVP processes, of which I'll say more shortly. Specific to our business, we continue to generate growth across the portfolio, with both reporting segments in all major geographies aside from China Once again, in positive territory. As has been the case now for the past several quarters, we converted good top-line performance into even stronger earnings growth. Behind continued factory and G&A productivity, growth in EBITDA margins grew 20 and 80 basis points respectively. EPS grew 25% in Q3 and is up more than 40% year-to-date. Free cash flow conversion remains strong in the quarters. supporting continued share repurchases. Net debt to adjusted EBITDA now stands at 0.6 times. Based on our strong momentum and year-to-date performance, we are once again raising our full-year profit and EPS guidance. Our updated 2026 expectations call for core growth of 3.75% to 4.25%, adjusted EBITDA growth of 12.5% to 14%, and adjusted EPS of $1.54 to $1.58, up more than 10% at the midpoint from our initial 2026 guide. Eric will say a bit more about the assumptions underlying our revised guidance in his section. Let's now turn to the progress we're making in support of our priorities of growth, operations and people. Starting with growth, SPARC was up $5 million. Diagnostics and implants were both up mid-single digits, and consumables grew low single digits against the high 2025 comp and following a strong H1. Geographically, developing markets ex-China were up high single digits, Europe grew in the mid-single digits, and consistent with my earlier comments, North America was up low single digits. Coming back to China... As expected, our business contracted at a low double-digit rate in Q3, principally driven by preparations for VVP, which is now underway. We expected a roughly $10 million impact from VVP in Q3, and that is about how things played out. The latest government communications point to mid-December timing for results to be announced. Although, as we know, due to the complexity of these processes, VVP timelines often run long. We expect VVP implementation most likely to commence in the first half of 2027. Turning now to operations, we continue to make progress on multiple fronts, underpinned by our Invista business system. Our price, procurement, and factory productivity efforts once again offset inflationary pressures and help to deliver growth and EBITDA margin expansion that I noted earlier. and we continue to make good progress on the tax front as well, with our effective tax rate down in the quarter almost six points versus Q3 of 2025. With respect to people, progress also remains strong. Last quarter, we opened a new European design center for Spark in Madrid, complementing facilities already operating in North America and Asia. We conducted more than 40 Kaizen events in Q3, including a CEO Kaizen that I was honored to host, covering a half-dozen projects across three continents. We also published our 2025 Sustainability Report, detailing the work we're doing to expand access to dental care, reduce environmental impact, and further increase investment in our colleagues and communities. Specific highlights include a 17% year-over-year reduction in lost time injuries, a 19% reduction in water consumption, and a 40% reduction in waste generation. The report also outlines the important work we're doing through the InVista Smile Project, serving close to 20,000 patients last year alone. We further built on this momentum in Q3 of this year, delivering care across multiple U.S. locations as well as internationally in Ghana, Mexico, Honduras, and Costa Rica. As we covered in some detail at our capital markets event in September, innovation is foundational to Invista's long-term growth strategy. We launched a number of new products across the first half of this year and the momentum continued in Q3 with several additional high-impact introductions. Slide 6 highlights just three of these. On the far left, Nomad Pro 3 is the next generation of our handheld x-ray system that created the category, bringing high-quality imaging directly to the chair side. Pro 3 delivers improved image quality with optimized exposure presets designed to support faster, more consistent workflows. As safety is fundamental in imaging, Nomad Pro 3 is engineered with multiple layers of protection, and delivers 10 times less rear-directed radiation than the leading competitor. In the middle of the page is our new Ultra HDL prismatic loop, the latest innovation from Horoscoptic. Prismatic loops are used by clinicians for more specialized procedures to achieve superior image clarity at higher magnifications. And the new Ultra HDL platform delivers this performance with a significantly lighter design. resulting in better ergonomics and greater comfort. Finally, the frame on the right provides an overview of our new endo module for DTX Studio. This module uses AI-assisted canal segmentation to identify and characterize precise tooth anatomy. Resulting insights help customers with clinical decision-making, treatment planning, and patient communications. Rook Canal Treatment is amongst the most common of endodontic procedures, with over 15 million performed last year in the U.S. alone. While general AI diagnostics are increasingly common in competitive systems, the depth and specificity of our latest endo module is unique and compelling. Early feedback from clinicians has been encouraging. Consistent with innovation's central role in our growth agenda, Thanks, Paul.
You're reading a preview of the NVST Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing